标题
Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas
作者
关键词
T cells, Melanomas, Melanoma cells, Cytokines, Immune cells, Blood, Lymphocytes, Cancer treatment
出版物
PLoS One
Volume 7, Issue 11, Pages e49878
出版商
Public Library of Science (PLoS)
发表日期
2012-11-27
DOI
10.1371/journal.pone.0049878
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Questionable Relevance of T Lymphocytes in Renal Cell Carcinoma
- (2014) B. A. Inman et al. JOURNAL OF IMMUNOLOGY
- Differentiation, phenotype, and function of interleukin-17-producing human V 9V 2 T cells
- (2011) N. Caccamo et al. BLOOD
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
- (2011) Arcadi Cipponi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V 9V 2 T-Cell Chemotaxis and Cytotoxicity In Vivo
- (2011) I. Benzaid et al. CANCER RESEARCH
- IL-21 enhances the potential of human γδ T cells to provide B-cell help
- (2011) Raj R. Bansal et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance
- (2011) Tetsuro Sasada et al. Immunotherapy
- Identification of a Novel Proinflammatory Human Skin-Homing V 9V 2 T Cell Subset with a Potential Role in Psoriasis
- (2011) U. Laggner et al. JOURNAL OF IMMUNOLOGY
- Presence of Tumor-Infiltrating Lymphocytes and a Dominant Nodule Within Primary Melanoma Are Prognostic Factors for Relapse-Free Survival of Patients With Thick (T4) Primary Melanoma
- (2010) Uma N. M. Rao et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Partial and Ineffective Activation of V 9V 2 T Cells by Mycobacterium tuberculosis-Infected Dendritic Cells
- (2010) S. Meraviglia et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy
- (2010) R. Speeckaert et al. Pigment Cell & Melanoma Research
- γδ T Cells and the Lymphoid Stress-Surveillance Response
- (2009) Adrian C. Hayday IMMUNITY
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V 9V 2 T Cells
- (2009) J. Li et al. JOURNAL OF IMMUNOLOGY
- Spontaneous regression of metastases from melanoma: review of the literature
- (2009) Louise Vennegaard Kalialis et al. MELANOMA RESEARCH
- A Rapid Crosstalk of Human γδ T Cells and Monocytes Drives the Acute Inflammation in Bacterial Infections
- (2009) Matthias Eberl et al. PLoS Pathogens
- Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
- (2008) Jaafar Bennouna et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR γδ cells
- (2008) Magdalena Kistowska et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
- (2008) J. Weber ONCOLOGIST
- Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)
- (2008) A. Ribas ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search